H.C. Wainwright analyst Robert Burns reiterated a Neutral rating on CytomX Therapeutics (NASDAQ: CTMX).The analyst commented: "Yesterday, CytomX announced a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE